Disease

Encephalomyelitis

Late-stage therapeutic developmentEmerging research

MeSHEncephalomyelitis

Publications

Clinical trials

Associated genes

2002

Latest publication

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this disease.

IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking.

Research2002-04-01Journal of immunology (Baltimore, Md. : 1950)

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low

Key developments

1 clinical trial expected to report results, the earliest in Q2 2027.

Upcoming Milestones

Q2 2027Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement

Major developments

Upcoming trial readoutImportant

Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target Engagement

Results expected Q2 20272026-06-22

Clinical Milestones1View

Results expected 1

2026-06-22Mechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target EngagementResults expected Q2 2027

Activity timeline1

2026-06-22ClinicalMechanistic Assessment of N-Acetylcysteine as an Antioxidant Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Through Dose Response and Treatment Target EngagementResults expected Q2 2027

Clinical trials

10 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme

All trials

Active

Late-stage

Completed

Late-stage studies

A Double-Blind, Randomized, Placebo-Controlled, Single-Center, Flexible Titration Study Evaluating the Efficacy of Solriamfetol in Treating Fatigue and Cognitive Symptoms in Adults Aged 18-65 Years With a Diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Phase 4 · Completed · Rochester Center for Behavioral Medicine

A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen®) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME)

Phase 3 · Completed · AIM ImmunoTech Inc.

Recruiting

An Exploratory, Placebo-controlled, Double-blind, Phase II Study of the Efficacy and Safety for Rituximab (Genetical Recombination) in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

Phase 2 · Recruiting · National Center of Neurology and Psychiatry, Japan

An Open Label Clinical Trial to Evaluate the Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease

N/A · Recruiting · Tongji Hospital

Recently completed

Phase 4 · Completed · Rochester Center for Behavioral Medicine

Effect of Stellate Ganglion Block on ME/CFS Symptoms and Metabolites

Phase 1 · Completed · Neuroversion, Inc.

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Phase 2 · Completed · Brigham and Women's Hospital

Pilot Phase 1/2, Open-Label, Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Phase 1/2 · Completed · LUCINDA BATEMAN, MD

Role of the NLRP3 Inflammasome Activation, Mitochondrial Biogenesis, and Immunoinflammatory Response After Oral Coenzyme Q10 Plus Selenium Supplementation in Individuals With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

N/A · Completed · Hospital Universitari Vall d'Hebron Research Institute

Phase 3 · Completed · AIM ImmunoTech Inc.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking.

Journal of immunology (Baltimore, Md. : 1950) · 2002 · 856 cites

Recent publications

IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking.

Journal of immunology (Baltimore, Md. : 1950) · 2002 · 856 cites

Leading journals1

Journal of immunology (Baltimore, Md. : 1950)1

Leading researchers6

Dufour JH1
Dziejman M1
Lane TE1
Leung JH1
Liu MT1
Luster AD1

Affiliations (unnormalised)1

Center for Immunology and Inflammatory Diseases1

Associated genes

1 match

Genes associated with this disease in the canonical knowledge graph (Open Targets evidence). Number shows the association score.

AKIRIN10.04

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

A general term indicating inflammation of the BRAIN and SPINAL CORD, often used to indicate an infectious process, but also applicable to a variety of autoimmune and toxic-metabolic conditions. There is significant overlap regarding the usage of this term and ENCEPHALITIS in the literature.

Identifiers

MeSHEncephalomyelitis

References & data sources

Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
Related entities are derived from literature co-mention (studied together) — associative, not causal.